Abstract
MS-Antigen 40 was given to 19 patients with perennial nasal allergy twice a week for a total of 15 times (total dose 550mg).
1. The clinical efficacy was rated as “good or moderate” in 73.7%.
2. Subjectively, 57.9% of the patients reported “good or moderate improvement”.
3. The general usefulness was considered “good or moderate” in 73.7%.
4. Side effects were noted in 15.8%. These were mild and all patients could continue taking the drug.
5. The only abnormal laboratory finding was an increase of WBC.
